Evidence map›Paper›PMID 37137847›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Different treatment strategies in patients with HBeAg-positive and negative chronic hepatitis B].

M Y Zhang, S Y Chen, Y M Sun, H You

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

M Y ZhangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
S Y ChenLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Y M SunLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
H YouLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Beijing Friendship Hospital · CNCapital Medical University · CN

Funding

Beijing Municipal Science & Technology Commission Z221100007422115
6 · The paper itself

Abstract

Patients with HBeAg-positive and negative chronic hepatitis B (CHB) have different immunological states and disease progression. Hence, the previously recommended antiviral therapy strategies for the two are different. In recent years, the antiviral indications have gradually eased, and the treatment goal has began to pursue clinical cure, as experts and scholars have gradually attached importance to the potential risk of disease progression in hepatitis B patients. Antiviral treatment strategies are gradually becoming uniform for patients with HBeAg-positive and negative. However, among them, HBeAg-negative patients can be combined with HBsAg quantification and other indicators to further screen the clinically cured dominant population in order to formulate the next treatment strategy.

Indexed as

Hepatitis B, ChronicAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansTreatment OutcomeAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensAntiviral therapyChronic hepatitis BFunctional cureHepatitis B e antigen

Identifiers

PMID37137847
PMCPMC12814080
OpenAlexW4368355611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.